(Q37696499)

22 August 2017

1 reference

title

Benefit-risk assessment: the use of clinical utility index (English)

1 reference

22 August 2017

Daniele Ouellet

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Drug Safety

22 August 2017

published in

1 reference

22 August 2017

volume

9

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

289-300

1 reference

Model-based drug development

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Paving the critical path: how can clinical pharmacology help achieve the vision?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

A two-part mixture model for longitudinal adverse event severity data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Modelling a spontaneously reported side effect by use of a Markov mixed-effects model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

The use of a clinical utility index to compare insomnia compounds: a quantitative basis for benefit-risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

The clinical utility index as a practical multiattribute approach to drug development decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

The use of clinical utility assessments in early clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Combining drug-disease and economic modelling to inform drug development decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

The use of multiattribute decision models in evaluating triptan treatment options in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

Model-based development of gemcabene, a new lipid-altering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903499265

10.1517/14740330903499265

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference